BioLife Solutions(BLFS) - 2024 Q1 - Quarterly Report

4J Table of Contents award of $6.8 million is being expensed on a straight-line basis over the grant date to the vesting date of December 31, 2024, excluding$1.6 million of expense recognized in 2023 to reflect accelerations in the vesting period of certain awards. On March 8, 2024, the Company granted 239,464 shares of market-based stock to its executives in the form of restricted stock. The shares granted contain a market condition based on TSR. The TSR market condition measures the Company's performance ...